Table 1

 Characteristics of trials in children included in the review

Study (year)DesignLanguage and countryJadad scoreNo (and age)
>of patients
Mean baseline severityDose of
>β agonist
Dose of anticholinergicCCS use
R, randomised; SB, single blind; DB, double blind; E, English; Sp, Spanish; F, French; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; NR, not reported; S, salbutamol; F, fenoterol; T, terbutaline; IB, ipratropium bromide; CCS, systemic corticosteroids.
Beck et al (1985)12R, DBE, Canada325 (6–17 y)FEV1 <50%S, 0.05 mg/kg q20 min Neb ×6IB, 0.25 mg Neb ×1No
Cook et al (1985)13R, DBE, Australia430 (18 m–12 y)NRF, 0.125–0.5 ml Neb ×1IB, 1–2 ml Neb ×1No
Reisman et al 1988)14R, DBE, Canada324 (5–15 y)FEV1 <55%S, 0.05 mg q20 min Neb ×6IB, 0.25 mg Neb ×3No
Watson et al (1988)15R, DBE, Canada331 (6–17 y)FEV1 30–70%F, 0.62 mg q60 min Neb ×2IB, 0.25 mg q60 min Neb ×2Yes
Phanichyakam et al
>(1990)16
R, DBE, Thailand120 (4–15 y)NRT, 0.5 mg MDI ×1IB, 0.04 mg MDI ×1No
Peterson et al
>(1994)17
R, DBE, Canada5163 (5–12 y)FEV1 <70%S, 3 mg q45 min Neb ×2IB, 0.25 mg q45 min Neb ×2Yes
Schuh et al (1995)18R, DBE, Canada580 (5–17 y)FEV1 <50%S, 0.15 mg/kg q20 min Neb ×3IB, 0.25 mg Neb ×1 or IB 0.25 mg Neb ×3No
Qureshi et al (1997)19R, DBE, USA590 (6–18 y)FEV1<50%S, 0.15 mg/kg q30 min Neb ×3IB, 0.5 mg Neb ×2Yes
Calvo et al (1998)20R, DBSp, Chile380 (18–55 y)PEF <80%S, 0.2 mg q15 min MDI ×4IB, 0.04 mg q15 min MDI ×4Yes
Ducharme et al (1998)21R, DBE, Canada5298 (2–18 y)Mild to moderateS, 0.07 mg/kg q30 min NebIB, 0.25 mg Neb ×1Yes
Qureshi et al (1998)22R, DBE, USA5434 (2–18 y)Moderate to severeS, 2.5–5 mg q20 min Neb ×3IB, 0.5 mg q20 min Neb ×2Yes
Zorc et al (1999)23R, DBE, USA5427 (1–17 y)Moderate to severeS, 2.5 mg q20 Neb ×3IB, 0.5 mg q20 min Neb ×3Yes
Benito Fernandez
>et al (2000)24
R, SBSp, Spain5102 (5 m–16 y)SevereS, 0.2 mg/kg q30 min Neb ×2IB, 0.25 mg q30 min Neb ×2Yes
SienraMonge
>et al (2000)25
R, DBSp, Mexico230 (8–15 y)Moderate to severeS, 0.2 mg q10 min MDI ×3IB, 0.02 mg q10 min MDI ×3No
Timsit et al (2002)26RF, France3114 (2–15 y)ModerateS, 0.15 mg/kg q20 min Neb ×6IB, 0.25 mg q20 min Neb ×3Yes
Sharma et al (2004)27RE, India250 (6–14 y)Moderate to severeS, 0.15 mg/kg q20 min Neb ×3IB, 0.25 mg q20 min Neb ×3No